tested positive for Covid /  experiencing symptoms again; This spontaneous case was reported by a patient and describes the occurrence of COVID-19 (tested positive for Covid /  experiencing symptoms again) in a 63-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 026A21A and 007M20A) for COVID-19 vaccination.     The patient's past medical history included Back pain. Previously administered products included for Product used for unknown indication: Sulfa. Past adverse reactions to the above products included Allergy with Sulfa. Concurrent medical conditions included Asthma, Arthritis and High cholesterol.   On 08-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 12-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 22-Nov-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 12-May-2022,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced COVID-19 (tested positive for Covid /  experiencing symptoms again). The patient was treated with NIRMATRELVIR, RITONAVIR (PAXLOVID) from 12-May-2022 to 17-May-2022 for COVID-19 treatment, at an unspecified dose and frequency. At the time of the report, COVID-19 (tested positive for Covid /  experiencing symptoms again) was resolving.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 12-May-2022, SARS-CoV-2 test: positive (Positive) positive. On 22-May-2022, SARS-CoV-2 test: positive (Positive) started experiencing symptoms again and still testing positive..         No concomitant medication was provided by the reporter.  Patient was tested positive for Covid on 12-May-2022 patient started paxlovid and took for 5 days. Felt better 6 days or so. On 22-May-2022 patient started experiencing symptoms again and still testing positive. Patient started feeling better on 27-May but still testing positive. Device date was reported as 27-May-2022  Company Comment: This is a spontaneous case concerning a 63-year-old female patient with no relevant medical history, who experienced the unexpected, non-serious adverse event of special interest of COVID-19, approximately 6 months after receiving the third dose of mRNA-1273 vaccine. The patient tested positive, received treatment of Nirmatrelvir/Ritonavir for 5 days and felt better. 5 days after completing the treatment, the patient reported to have recurrence of symptoms and tested positive. The patient started to feel better after 5 days but still tested positive. The patient received the first two doses of mRNA-1273 vaccine on a 32-day interval with the second dose administered approximately 8 months prior to the third dose. The benefit-risk relationship of mRNA-1273 is not affected by this report.; Sender's Comments: This is a spontaneous case concerning a 63-year-old female patient with no relevant medical history, who experienced the unexpected, non-serious adverse event of special interest of COVID-19, approximately 6 months after receiving the third dose of mRNA-1273 vaccine. The patient tested positive, received treatment of Nirmatrelvir/Ritonavir for 5 days and felt better. 5 days after completing the treatment, the patient reported to have recurrence of symptoms and tested positive. The patient started to feel better after 5 days but still tested positive. The patient received the first two doses of mRNA-1273 vaccine on a 32-day interval with the second dose administered approximately 8 months prior to the third dose. The benefit-risk relationship of mRNA-1273 is not affected by this report.